13. Long-term efficacy, safety and predictors of response to amivantamab among patients with post-platinum EGFR exon 20 insert (Ex20ins)-mutated advanced non-small cell lung cancer (aNSCLC) — CHRYSALIS (NCT02609776)
P Garrido, Rachel E Sanborn, See full list of authors in comments
Dive into the research topics of '13. Long-term efficacy, safety and predictors of response to amivantamab among patients with post-platinum EGFR exon 20 insert (Ex20ins)-mutated advanced non-small cell lung cancer (aNSCLC) — CHRYSALIS (NCT02609776)'. Together they form a unique fingerprint.